EU approves Synjardy (empagliflozin plus metformin) for treatment of Type 2 Diabetes-Boehringer
Synjardy (empagliflozin plus metformin) from Boehringer has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union (EU). Synjardy is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance. Synjardy combines empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), commonly prescribed for the treatment of T2D. Empagliflozin was approved in the EU in May 2014 and is available in many countries as an oral, once-daily tablet, marketed as Jardiance.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins